U.K. regulators have launched a study into a possible genetic link between use of GLP-1s, such as Ozempic, Mounjaro and Wegovy, and acute pancreatitis.
Yellow Card Biobank, a joint initiative of Genomics England and the government, is calling for patients across the U.K. who have been hospitalized with acute pancreatitis after taking GLP-1s to participate, according to a June 26 news release from the Medicines & Healthcare Products Regulatory Agency. Healthcare professionals were also urged to submit reports and assist with recruitment.
Those reporting will be asked to submit saliva samples for genetic analysis, with the aim of identifying whether specific genetic traits are linked to adverse reactions to the medications.
“Almost a third of side effects to medicines could be prevented with the introduction of genetic testing,” said Alison Cave, PhD, chief safety officer for MHRA.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.